STRONG EVIDENCE

Pimecrolimus (Elidel)

Also discussed as: pimecrolimus, Pimecrolimus, elidel, Elidel, Elidel cream, pimecrolimus cream

Pimecrolimus is considered an effective option for long-term treatment of eczema, particularly in sensitive areas like the face. It has anti-pruritic effects and can improve skin hydration and epidermal differentiation.

Evidence grade · papers only

STRONG EVIDENCE

11 level-I · 24 level-II · 5 level-IV · 2 level-VI · 1 level-III · 3 level-VII

Research base (design-resolved): 11 systematic review/meta-analysis, 24 randomized trials, 8 observational/descriptive.

Community interest · posts only

moderate · 4,326 mentions

Most discussed for: topical_prescription, topical_otc, oral_medication

What the research says

Topical tacrolimus and pimecrolimus have anti-pruritic effects and are considered good options for long-term treatment.

Radhakrishnan et al. (2024), International Journal of Molecular Sciences. doi:10.3390/ijms25105375 · verified

TCIs are favorable for sensitive areas such as the face.

Çetinarslan et al. (2023), Frontiers in Molecular Biosciences. doi:10.3389/fmolb.2023.1159404 · verified

TCIs are recommended for use in more sensitive areas such as the face and genitals. (n=2)

Soares et al. (2023), Journal of Clinical Medicine. doi:10.3390/jcm12103419 · verified

Pimecrolimus improved skin hydration and epidermal differentiation.

Beck et al. (2022), JID Innovations. doi:10.1016/j.xjidi.2022.100131 · verified

Topical calcineurin inhibitors are effective for the prevention and reduction of AD exacerbation.

Kulthanan et al. (2021), Asian Pacific Journal of Allergy and Immunology. doi:10.12932/ap-010221-1050 · verified

Topical calcineurin inhibitors are effective for inflammation in atopic dermatitis.

Tamagawa‐Mineoka et al. (2020), International Journal of Molecular Sciences. doi:10.3390/ijms21082671 · verified

Pimecrolimus was shown to be superior to vehicle.

Nankervis et al. (2016), Programme Grants for Applied Research. doi:10.3310/pgfar04070 · verified

What the community reports

Experience reports, not evidence. Volumes from 1.1M triaged posts.

topical_prescription
topical_otc
oral_medication
biologic

Safety and side effects

Some users may experience a burning sensation at the application site, which can be mild or transient.

For infants and children

Pimecrolimus is approved for use in children aged 2 years and older.

Studied protocols

As reported in the papers, not recommendations.

frequency: twice daily; route: topical; duration: 4 weeks

Lai et al. (2025), Frontiers in Pharmacology

route: topical

Boguniewicz et al. (2011), Immunological Reviews

dose: 1% cream; frequency: twice daily; route: topical; duration: up to 6 weeks

Ashcroft et al. (2005), BMJ

dose: 1%; frequency: twice daily; route: topical; duration: up to 6 weeks

Garside et al. (2005), Health Technology Assessment

dose: 1% cream; frequency: twice daily until lesions subside, not longer than 6 weeks; route: topical; duration: not longer than 6 weeks

Gutfreund et al. (2013), Advances in Dermatology and Allergology

frequency: twice daily; route: topical

Afshari et al. (2024), Frontiers in Immunology

Drawn from 45 papers · generated 2026-06-11T12:40:21.211381+00:00 · phrasing by gpt-4o-mini, every number computed from the database and every citation machine-verified.